The Immune Response Corporation, Inc. Extends Warrants Exercise Deadline
Published: Mar 01, 2007
CARLSBAD, Calif., Feb. 28 /PRNewswire-FirstCall/ -- The Immune Response Corporation today announced that it has extended to March 30, 2007 the expiration date of the 6,000,000 second tranche warrants issued in connection with its 2006 private placement offering. The second tranche warrants previously were set to expire March 1, 2007. If fully exercised, the second tranche warrants, which first became exercisable on October 16, 2006, could provide the Company with additional gross proceeds of $12,000,000.
Before the Company's December 2006 1-for-100 reverse stock split, these warrants had been exercisable for 600,000,000 shares of common stock.
About The Immune Response Corporation
The Immune Response Corporation is an immuno-pharmaceutical company focused on developing products to treat autoimmune and infectious diseases. The Company's lead immune-based therapeutic product candidates are NeuroVax(TM) for the treatment of MS and REMUNE(R) and IR103 for the treatment of HIV infection. These therapies are in Phase II clinical development and are designed to stimulate disease pathogen-specific immune responses aimed at slowing or halting the rate of disease progression.
NeuroVax(TM), which is based on the Company's patented T-cell receptor (TCR) peptide vaccine technology, has shown potential clinical value in the treatment of relapsing forms of MS. NeuroVax(TM) has been shown to stimulate strong, disease-specific cell-mediated immunity in nearly all patients treated and appears to work by enhancing levels of FOXP3+ Treg cells that are able to down regulate the activity of pathogenic T-cells that cause MS. Increasing scientific findings have associated diminished levels of FOXP3+ Treg cell responses with the pathogenesis and progression of MS and other autoimmune diseases such as rheumatoid arthritis (RA), psoriasis and Crohn's disease. In addition to MS, the Company has open Investigational New Drug Applications (IND) with the FDA for clinical evaluation of TCR peptide-based immune-based therapies for RA and psoriasis.
REMUNE(R) and IR103 are based on the Company's patented, whole-inactivated virus technology, co-invented by Dr. Jonas Salk and indicated to be safe and immunogenic in extensive clinical studies of REMUNE(R), the Company's first generation HIV product candidate. IR103 is a second-generation formulation that combines its whole-inactivated antigen with a synthetic Toll-like receptor (TLR-9) agonist designed to create enhanced HIV-specific immune responses. The Company is currently testing REMUNE(R) and IR103 in two Phase II clinical studies as a first-line treatment for drug-naive HIV-infected individuals not yet eligible for antiretroviral therapy according to current medical guidelines.
NeuroVax(TM), REMUNE(R) and IR103 are in clinical development by The Immune Response Corporation and are not approved by any regulatory agencies in any country at this time. Please visit The Immune Response Corporation at www.imnr.com for additional information.
This news release contains forward-looking statements. Forward-looking statements are often signaled by forms of words such as should, could, will, might, plan, projection, forecast, expect, guidance, potential and developing. Actual results could vary materially from those expected due to a variety of risk factors, including whether the Company will continue as a going concern and successfully raise proceeds from financing activities sufficient to fund operations and additional clinical trials of NeuroVax(TM), REMUNE(R) or IR103, the uncertainty of successful completion of any such clinical trials, the fact that the Company has not succeeded in commercializing any drug, the risk that NeuroVax(TM), REMUNE(R) or IR103 might not prove to be effective as either a therapeutic or preventive vaccine, whether future trials will be conducted and whether the results of such trials will coincide with the results of NeuroVax(TM), REMUNE(R) or IR103 in preclinical trials and/or earlier clinical trials. A more extensive set of risks is set forth in The Immune Response Corporation's SEC filings including, but not limited to, its Annual Report on Form 10-K for the year ended December 31, 2005, and its subsequent Quarterly Reports filed on Form 10-Q. The Company undertakes no obligation to update the results of these forward-looking statements to reflect events or circumstances after today or to reflect the occurrence of unanticipated events.
REMUNE(R) is a registered trademark of The Immune Response Corporation. NeuroVax(TM) is a trademark of The Immune Response Corporation.
MEDIA CONTACT: Rachel Kessler Chamberlain Communications Group Inc. (212) 389-9155 email@example.com INVESTOR CONTACTS: Robert Giordano ROI Associates (212) 495-0201 firstname.lastname@example.org Gene Marbach Makovsky & Company (212) 508-9645 email@example.com COMPANY CONTACT: Michael K. Green, COO The Immune Response Corporation (760) 431-7080 firstname.lastname@example.orgThe Immune Response Corporation
CONTACT: Media, Rachel Kessler of Chamberlain Communications Group Inc.,+1-212-389-9155, email@example.com, for The Immune ResponseCorporation; or Investors, Robert Giordano of ROI Associates,+1-212-495-0201, firstname.lastname@example.org; or Gene Marbach of Makovsky &Company, +1-212-508-9645, email@example.com, both for The ImmuneResponse Corporation; or Michael K. Green, COO of The Immune ResponseCorporation, +1-760-431-7080, firstname.lastname@example.org
Web site: http://www.imnr.com/